These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 6113911)

  • 1. Physiologic disposition of pergolide.
    Rubin A; Lemberger L; Dhahir P
    Clin Pharmacol Ther; 1981 Aug; 30(2):258-65. PubMed ID: 6113911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologic disposition of lergotrile.
    Rubin A; Lemberger L; Dhahir P; Warrick P; Crabtree RE; Obermeyer BD; Wolen RL; Rowe H
    Clin Pharmacol Ther; 1978 Mar; 23(3):272-80. PubMed ID: 627132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pergolide, a potent long-acting dopamine-receptor agonist.
    Lemberger L; Crabtree R; Callaghan JT
    Clin Pharmacol Ther; 1980 May; 27(5):642-51. PubMed ID: 7189453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia.
    Lamberts SW; Quik RF
    J Clin Endocrinol Metab; 1991 Mar; 72(3):635-41. PubMed ID: 1997518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic effects on kidney function and responsiveness of aldosterone, plasma renin activity, prolactin, catecholamines, and blood pressure to stimulation in patients with prolactinoma. Comparison of the efficacy of pergolide and bromocriptine therapy.
    Jungmann E; Haak T; Althoff PH; Fassbinder W; Schöffling K
    Arzneimittelforschung; 1988 Feb; 38(2):296-300. PubMed ID: 3285838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pergolide mesylate: its effects on circulating anterior pituitary hormones in man.
    Perryman RL; Rogol AD; Kaiser DL; MacLeod RM; Thorner MO
    J Clin Endocrinol Metab; 1981 Oct; 53(4):772-8. PubMed ID: 6793609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-acting dopamine agonist pergolide mesylate for treatment of hyperprolactinaemia.
    Bergh T; Nillius SJ; Wide L
    Acta Eur Fertil; 1984; 15(6):421-4. PubMed ID: 6536135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pergolide mesylate: a potent day-long inhibitor of prolactin in rhesus monkeys and patients with Parkinson's disease.
    Kleinberg DL; Lieberman A; Todd J; Greising J; Neophytides A; Kupersmith M
    J Clin Endocrinol Metab; 1980 Jul; 51(1):152-4. PubMed ID: 6769937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of prolactin and growth hormone on rat mammary tumors induced by N-nitrosomethylurea.
    Rose DP; Noonan JJ
    Cancer Res; 1982 Jan; 42(1):35-8. PubMed ID: 6797725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of [3H]pergolide mesylate to dopamine receptors of mammalian brains.
    Wong DT; Bymaster FP; Lane PT; Kau D; Bach NJ; Kornfeld EC
    Res Commun Chem Pathol Pharmacol; 1980 Nov; 30(2):195-210. PubMed ID: 7444158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease.
    Lieberman AN; Neophytides A; Leibowitz M; Gopinathan G; Pact V; Walker R; Goodgold A; Goldstein M
    Adv Neurol; 1983; 37():95-108. PubMed ID: 6858782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent 48 hours inhibition of prolactin secretion by pergolide in hyperprolactinaemic women.
    L'Hermite M; Debusschere P
    Acta Endocrinol (Copenh); 1982 Dec; 101(4):481-3. PubMed ID: 7158225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ergoline derivatives on intraocular pressure and iris function in rabbits and monkeys.
    Potter DE; Burke JA
    Curr Eye Res; 1982-1983; 2(5):281-8. PubMed ID: 6131794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the metabolism of ergoline derivatives. Metabolism of nicergoline in man and in animals.
    Arcamone F; Glässer AG; Grafnetterova J; Minghetti A; Nicolella V
    Biochem Pharmacol; 1972 Aug; 21(16):2205-13. PubMed ID: 4630400
    [No Abstract]   [Full Text] [Related]  

  • 15. Dopamine agonist activities of pergolide, its metabolites, and bromocriptine as measured by prolactin inhibition, compulsive turning, and stereotypic behavior.
    Clemens JA; Okimura T; Smalstig EB
    Arzneimittelforschung; 1993 Mar; 43(3):281-6. PubMed ID: 8489554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The disposition of l-3-[(dimethylamino)-(m-dioxan-5-yl)methyl]pyridine in man.
    Rubin A; Dhahir PH; Crabtree RE; Henry DP
    Drug Metab Dispos; 1979; 7(3):149-54. PubMed ID: 38085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition and biotransformation of quinpirole, a new D-2 dopamine agonist antihypertensive agent, in mice, rats, dogs, and monkeys.
    Whitaker NG; Lindstrom TD
    Drug Metab Dispos; 1987; 15(1):107-13. PubMed ID: 2881745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia.
    Franks S; Horrocks PM; Lynch SS; Butt WR; London DR
    Br Med J (Clin Res Ed); 1983 Apr; 286(6372):1177-9. PubMed ID: 6404378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microbial transformations of pergolide to pergolide sulfoxide and pergolide sulfone.
    Smith RV; Davis PJ; Kerr KM
    J Pharm Sci; 1983 Jul; 72(7):733-6. PubMed ID: 6684155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of hyperprolactinemia with pergolide.
    Mattox JH; Bernstein J; Buckman MT
    Int J Fertil; 1986; 30(4):39-43. PubMed ID: 2890594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.